{"id":"tp-58611","type":"article-newspaper","title":"CG Oncology Shares Rise About 9% After Phase 3 Bladder Cancer Data","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/58611","datePublished":"2026-11-16T16:41:19.000Z","dateModified":"2026-11-16T16:41:19.000Z","language":"en","abstract":"The data involved cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy for non-muscle invasive bladder cancer.","section":"Business","references":[]}